Orexigen Therapeutics (OREX) tumbles as halt called to tests

Orexigen Therapeutics, Inc. OREX fell 14.7% to $5.06. The company terminated a cardiovascular outcomes trial of its anti-obesity drug Contravene, from which interim results were inadvertently released earlier this year. The trial is not being terminated because of a finding of superiority or harm. An additional trial is expected to be completed in 2020. Share volume came in at 9.2 million, besting an all-day average of 5.8 million